Lexicon hosted its Q1 earnings call and provided updates to their T1DM and T2DM diabetes development programs for sotagliflozin and LX2761.
Lilly hosted its Q1 ’17 earnings call and provided an update to its diabetes portfolio including pipeline and LCM activities.
A Lilly sponsored Ph1 ClinicaTrials.gov record has been observed for LY3325656. According to the record, the compound is dosed orally and is being compared to liraglutide and in combination with sitagliptin. MOA for LY3325656 remains to be determined.
J&J presented its Q1 ’17 earnings results and provided a brief update to its diabetes business including drugs and devices. Of note, J&J is hosting its Pharmaceutical Business Review on May 17.
The ClincalTrials.gov record for the CREDENCE trial has been updated to reflect a later primary completion date. The estimated primary completion date has been pushed back from February 11, 2019 to June 28, 2019, which may be due to trial recruitment.
Lilly has announced intentions to invest $850M in its US operations in 2017 including $85M to expand the Trulicity device assembly operations. Additionally, Lilly announced the dedication of a $140M insulin cartridge facility.
Lilly and the William Sansum Diabetes Center in Santa Barbara, California have entered into a research collaboration to further understand the unmet needs related to diabetes in the Latino population.
Lexicon hosted its Q4 and full-year 2016 earnings call and provided an update to its diabetes pipeline.
Merck/Pfizer quietly filed their SGLT2i, ertugliflozin, FDC with metformin, and FDC with Januvia (sitagliptin) in December 2016.
Lexicon recently presented at the Leerink Global Healthcare Conference and provided updates to its diabetes development programs.